Phase 3 N=97 Prospective Study of Patients With Thrombocytopenia Following HSCT
Thrombocytopenia · Hematologic Diseases
Primary: Number of Participants With Platelet Count Recovery — 20; 22; 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=285 Study Comparing Lutonix AV Drug Coated Balloon vs Standard Balloon for Treatment of Dysfunctional AV Fistulae
Arteriovenous Fistula
Primary: Percentage of Participants With Target Lesion Primary Patency (TLPP) at 6 Months Post Index Procedure — 71.4; 63 Percentage of Participants — p=0.0562
Phase 3 N=663 Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Lung Diseases, Interstitial
Primary: Annual Rate of Decline in Forced Vital Capacity - Overall Population — -80.82; -187.78 Milliliter per year — p=<.0001
Phase 3 N=766 A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)
Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ
Primary: Base Stage: Geometric Mean Titers for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18: Competitive Luminex Immunoassay (cLIA) — 975.2; 686.6; 807.4; 580.2…
Phase 3 N=622 Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
Metastatic Triple Negative Breast Cancer
Primary: Overall Survival in Participants With Programmed Cell Death Ligand 1 (PD-L1) With Combined Positive Score (CPS) ≥10 — 12.7; 11.6 Months — p=0.0574
Phase 3 N=144 Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer
Prostatic Neoplasms
Primary: Efficacy of Leuprolide Mesylate (LMIS 25mg) — 97.9 Percentage of participants
Phase 3 N=258 A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Primary: Complete Remission Rate in Participants Not Previously Treated With BCRi Therapy - Primary Analysis — 35.1 percentage of participants — p=<0.001
Phase 3 N=167 Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease
Renal Insufficiency, Chronic · Iron-Deficiency Anemia
Primary: Change in Hb Concentration From Baseline to Week 16 — 0.50; -0.02 g/dl — p=0.0149
Phase 3 N=1,392 A Study of LY900014 in Participants With Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 — -0.13; 0.08; -0.05 Percentage of HbA1c — p=0.060
Phase 3 N=62 Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
Heterozygous Familial Hypercholesterolemia
Primary: Change in Standardized Rate of Apheresis Treatments From Week 7 to Week 18 — 0.806; 0.128 Treatments — p=< 0.0001
Phase 3 N=331 Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease
Crohn's Disease
Primary: Remission at Week 26 — 61; 37 Participants — p=0.0048
Phase 3 N=150 Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia
Hyperkalemia
Primary: Number of Patients Who Experienced Adverse Events (AEs) in the MP — 131; 2; 27; 9 Participants
Phase 3 N=119 To Evaluate Oral Health and Quality of Life Associated With Use of a Denture Adhesive
Denture Retention
Primary: Gum Health Analysis by Change From Baseline in Overall Mean Scores of Participant Responses to the Gum Comfort Questionnaire After 12 Weeks — 4.1; 4.5; -0.6; -0.4 Score…
Phase 3 N=26 Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis
Non-Infectious Uveitis
Primary: The Utilization of the Mk II Inserter From the Day of Treatment Through 7 Days Following Treatment. — 10; 3; 3; 2 Eyes
Phase 3 N=335 A Multi-Center Study Of CD07743 for the Improvement of Lateral Canthal Lines (CROW'S FEET)
Canthal Lines
Primary: Number of Responders on the Severity of Lateral Canthal Lines "at Maximum Smile". — 119; 6 Participants